Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial - Concepedia

Concepedia

Publication | Closed Access

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

291

Citations

25

References

2017

Year

Félix Ratjen, Christopher Hug, Gautham Marigowda, Simon Tian, Xiaohong Huang, Sanja Stanojevic, Carlos Milla, Paul D. Robinson, David Waltz, Jane C. Davies,

The Lancet Respiratory Medicine

Pulmonary FibrosisMedicinePlacebo-controlled Phase 3

References

	Year	Citations

Page 1